Phase 4Recruiting

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination (GLYCO-3P)

Sponsor
Nabiqasim Industries (Pvt) Ltd (Industry)
Enrollment
800 planned
Conditions
Diabetes Mellitus; Type 2 DM
Interventions
Empagliflozin+Linagliptin+Metformin
Ages
adults, older adults
Registry
NCT06862739

Full record on ClinicalTrials.gov

From the registry

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Primary outcomes

  • Changes in HbA1c levels

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered